Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook

Published 28/04/2022, 12:52
© Reuters.  Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook
MRK
-
MRCG
-
MKKGY
-
MRCK34
-

  • Merck & Co Inc's (NYSE: MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%.
  • Pharmaceutical sales increased 53% to $14.11 billion, primarily driven by molnupiravir, oncology, vaccines, and hospital acute care products.
  • Pharmaceutical sales growth, excluding Lagevrio sales, was 18%. COVID-19 treatment drug Lagevrio (molnupiravir) sales were $3.2 billion.
  • Growth in oncology was primarily driven by higher sales of Keytruda, which rose 23% to $4.8 billion.
  • Vaccine sales rebounded, and Gardasil/ Gardasil 9 sales were up 59% to $1.5 billion, primarily driven by strong global demand, particularly in China.
  • Adjusted EPS of $2.14 also surpassed the analysts' estimate of $1.83 and was up from $1.16 posted a year ago.
  • 2022 Guidance: Merck expects FY22 sales of $56.9 billion - $58.1 billion, compared to prior guidance of $56.1 billion - $57.6 billion and the consensus of $57.35 billion.
  • The guidance includes expected sales of $5 billion - $5.5 billion from Lagevrio, compared to the earlier outlook of $5 billion - $6 billion.
  • It expects an adjusted EPS of $7.24 - $7.36 versus the previous range of $7.12 - $7.27 (consensus $7.24).
  • Price Action: MRK shares are up 1.88% at $86.00 during the premarket session on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.